Effect of beta blocker therapy on survival of patients with heart failure and preserved systolic function following hospitalization with acute decompensated heart failure

European Journal of Internal Medicine
Roman NevzorovVictor Novack

Abstract

The importance of heart failure with preserved ejection fraction is being increasingly recognized. However, there is a paucity of data about effective treatment for this condition. The present study investigated the impact of beta blocker therapy for 3 months before admission on the two-year survival of patients with heart failure and preserved systolic function hospitalized due to decompensated heart failure. We performed a retrospective cohort analysis of 345 consecutive patients with heart failure with preserved systolic function older than 18 years hospitalized due to decompensated heart failure. Two groups of patients were compared: those who received beta blockers within 3 months before admission (BB) and those who did not (NBB). The primary outcome was two year all cause mortality (maximal follow-up available in all subjects). To adjust for a potential misbalance between BB and NBB groups in baseline characteristics, a propensity score for beta blocker therapy was incorporated into the survival model. 154 patients (44.6%) received beta blockers prior to admission. Overall two year mortality rate in the BB group was 50% vs. 62.8% in the NBB group, log-rank test p = 0.016. Beta blockers showed protective effect on two-year...Continue Reading

References

Dec 1, 1995·Journal of the American College of Cardiology·R S VasanD Levy
Jan 30, 2004·Annual Review of Medicine·William H Gaasch, Michael R Zile
Jul 21, 2006·The New England Journal of Medicine·Theophilus E OwanMargaret M Redfield
Jul 21, 2006·The New England Journal of Medicine·R Sacha BhatiaPeter P Liu
Feb 17, 2009·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Oleg GorelikNatan Cohen
Mar 21, 2009·Circulation. Heart Failure·Danielle M HenkelVéronique L Roger

❮ Previous
Next ❯

Citations

May 6, 2011·Internal and Emergency Medicine·Chiara LazzeriGian Franco Gensini
Jul 19, 2014·Heart Failure Reviews·Chirag BavishiFranz H Messerli
Jan 18, 2018·Journal of the American Heart Association·Dongze ZhangYu-Long Li
Sep 13, 2013·American Journal of Physiology. Cell Physiology·Huiyin TuYu-Long Li
Aug 8, 2018·European Heart Journal·Christopher J RushJohn J V McMurray
Jun 26, 2018·European Journal of Pharmacology·Dongze ZhangYu-Long Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.